These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. [Cervix uteri cancer in Poland--epidemiological opening balance and perspectives]. Didkowska J, Wojciechowska U, Zatoński W. Ginekol Pol; 2006 Sep; 77(9):660-6. PubMed ID: 17219794 [Abstract] [Full Text] [Related]
28. Self-reported history of Pap-smear in HIV-positive women in Northern Italy: a cross-sectional study. Dal Maso L, Franceschi S, Lise M, De' Bianchi PS, Polesel J, Ghinelli F, Falcini F, Finarelli AC, Screening of HIV-positive women in Emilia-Romagna (SHER) Study. BMC Cancer; 2010 Jun 21; 10():310. PubMed ID: 20565935 [Abstract] [Full Text] [Related]
29. Costs and benefits of different strategies to screen for cervical cancer in less-developed countries. Mandelblatt JS, Lawrence WF, Gaffikin L, Limpahayom KK, Lumbiganon P, Warakamin S, King J, Yi B, Ringers P, Blumenthal PD. J Natl Cancer Inst; 2002 Oct 02; 94(19):1469-83. PubMed ID: 12359856 [Abstract] [Full Text] [Related]
30. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgren K, Rådberg T, Strander B, Johansson B, Forslund O, Hansson BG, Rylander E, Dillner J. N Engl J Med; 2007 Oct 18; 357(16):1589-97. PubMed ID: 17942872 [Abstract] [Full Text] [Related]
32. Risk-adapted primary HPV cervical cancer screening project in Wolfsburg, Germany--experience over 3 years. Luyten A, Scherbring S, Reinecke-Lüthge A, Braun BE, Pietralla M, Theiler K, Petry KU. J Clin Virol; 2009 Nov 18; 46 Suppl 3():S5-10. PubMed ID: 20129072 [Abstract] [Full Text] [Related]
36. Prevalence of positive screening test results and agreement between cytology and human papillomavirus testing in primary cervical cancer screening in North-Western Romania. Şuteu O, Blaga ML, Nygård M, Leinonen MK, Nicula F, Păiş R, Coza D, Cadariu PA, Melnic A, Andreassen T, Hashim D, Weiderpass E. Eur J Cancer Prev; 2020 Mar 18; 29(2):141-148. PubMed ID: 31033568 [Abstract] [Full Text] [Related]
37. Community-based screening of cervical cancer in a low prevalence area of India: a cross sectional study. Yasmeen J, Qurieshi MA, Manzoor NA, Asiya W, Ahmad SZ. Asian Pac J Cancer Prev; 2010 Mar 18; 11(1):231-4. PubMed ID: 20593962 [Abstract] [Full Text] [Related]
39. Benefits and costs of using HPV testing to screen for cervical cancer. Mandelblatt JS, Lawrence WF, Womack SM, Jacobson D, Yi B, Hwang YT, Gold K, Barter J, Shah K. JAMA; 2002 May 08; 287(18):2372-81. PubMed ID: 11988058 [Abstract] [Full Text] [Related]
40. [Cervical Pap smear in an epidemiologically exposed population: ideas, facts and arguments]. Doris B, Boyer L, Lavoué V, Riou F, Henno S, Tas P, Sévène L, Levêque J. J Gynecol Obstet Biol Reprod (Paris); 2014 Jan 08; 43(1):26-34. PubMed ID: 24332738 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]